Concern About the Adverse Effects of Thrombocytopenia and Thrombosis After Adenovirus-Vectored COVID-19 Vaccination

Haimei MA, MD

Abstract
Since the outbreak of Covid-19 in December, 2019, scientists worldwide have been committed to developing COVID-19 vaccines. Only when most people have immunity to SARS-CoV-2, COVID-19 can reduce even wholly overcome. So far, nine kinds of COVID-19 vaccines have passed the phase III clinical trials and have approved for use. At the same time, adverse reactions after COVID-19 vaccination have also reported. This paper focuses on the adverse effects of thrombosis and thrombocytopenia caused by the COVID-19 vaccine, especially the adenovirus-vector vaccine from AstraZeneca and Pfizer, and discusses its mechanism and possible countermeasures.

Keywords
COVID-19, SARS-CoV-2, adenovirus-vector vaccine, adverse effect, thrombocytopenia, thrombosis

Date received: 19 June 2021; revised: 18 July 2021; accepted: 29 July 2021.

COVID-19 Vaccine Types and Preparation Methods

COVID-19 Vaccine Types

The following nine vaccines have completed phase III clinical trials and have approved by the World Health Organization (WHO). The effectiveness of the various vaccines and other relevant information shows in Table 1.

COVID-19 Vaccine Preparation Methods

Currently, there are three types of COVID-19 vaccine approved worldwide: inactivated vaccine, adenovirus-vector vaccine and nucleic acid vaccine.11

The inactivated COVID-19 vaccine made from native SARS-Cov-2, which is heated or chemically treated to make its replication defective, thus maintaining the immunogenicity of the SARS-Cov-2 but without causing pathogenicity.

The adenovirus-vector COVID-19 vaccine is to insert part of the gene sequence of SARS-Cov-2 into the adenovirus, in order to construct a fusion type of the two viruses so that it has the infectivity of adenovirus and expresses the antigenicity of SARS-Cov-2.

The mRNA COVID-19 vaccine consists of a nucleoside-modified mRNA encoding SARS-Cov-2, packaged in lipid nanoparticles to reduce RNA degradation and improve translation efficiency.

Adverse Effects of COVID-19 Vaccine

The results of clinical trials on the safety and effectiveness of COVID-19 vaccines have reported one after another. Under the premise of fully affirming the immune protection of the COVID-19 vaccine, the adverse effects cannot ignored.

The most common symptoms after COVID-19 vaccination are fatigue, headache, muscle pain, chills and pain at the injection site, which described in the safety evaluation reports of COVID-19 vaccines such as Pfizer and Moderna and other vaccines.9,12

Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China

Corresponding Author:
Haimei MA, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, No.168 Litang Road, Changping District, Beijing 102218, China.
Email: mhm69@126.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Scholars conducted a descriptive analysis of the WHO global individual case safety report database VigiBase, reporting the arterial and venous thrombosis adverse effects of COVID-19 vaccination. The thrombosis adverse reactions mainly occurred after vaccination with Pfizer, AstraZeneca and Moderna these adenovirus-vector mRNA vaccines.13

To Discuss the Mechanism of Adenovirus-Vectored Vaccine Inducing Thrombocytopenia and Thrombosis

Thrombosis and Thrombocytopenia After AstraZeneca’s COVID-19 Vaccination

The incidence of thrombotic events per million people after COVID-19 vaccination was 0.21 [95% CI:0.19-0.22]. For VTE (venous thrombus embolism) and ATE (arterial thrombus embolism), there were, respectively, 0.075 [95% CI: 0.07-0.08] and 0.13 [95% CI: 0.12-0.14].13

On March 19, 2021, the European Medicines Agency (EMA) disclosed to the public two deaths after AstraZeneca’s COVID-19 vaccination.14 A 49-year-old woman died of severe coagulopathy dysfunction and a 35-year-old woman died of pulmonary embolism. It found that patients with cerebral thrombosis after AstraZeneca’s vaccination has the characteristic that they appeared decreased platelet count. On April 10, two simultaneous studies, published in the New England Journal of Medicine (NEJ), discussed symptoms of thrombosis and thrombocytopenia following AstraZeneca’s COVID-19 vaccination, and for the first time reported on the underlying mechanism.15,16

Vaccine-Induced Immune Thrombotic Thrombocytopenia

It has confirmed that COVID-19 is associated with a prethrombotic phenotype characterized by coagulation dysfunction and endothelial dysfunction.17-21 In the NEJ reports, all 11 patients in the initial analysis had moderate to severe thrombocytopenia and abnormal thrombosis, especially cerebral venous thrombosis and visceral venous thrombosis. In addition, five patients also had disseminated intravascular coagulation (DIC), with the significantly higher D-dimer level and one or more of the INR (international standardized ratio) of PT (prothrombin time) or fibrinogen level abnormal.15,16

When evaluating the serological characteristics of the four initial patients by the platelet activation assay, found that platelet factor 4 (PF4) significantly enhanced the response and platelet activation. All reactions were blocked by monoclonal antibody and immunoglobulin, indicating that platelet activation occurs through platelet Fc receptors. The PF4-heparin ELISA tests of these patients were positive. Most samples (19 out of 24) inhibited by LMWH (low molecular weight heparin). Almost all models (22 out of 24) activated by adding PF4 and inhibiting by high doses of heparin.

This increased PF4 antibody level mediated thrombocytopenia and thrombosis is similar to the heparin-induced thrombocytopenia (HIT). HIT is an immune complication of heparin therapy caused by PF4 and heparin complex antibodies.22,23 PF4-heparin antibody binds and activates FcγRIIA on platelets and monocytes and mediates HIT and thrombosis.24

It is precise because the clinical manifestations of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination and the production of peculiar auto anti-PF4 antibodies are very similar to HIT. This syndrome is named vaccine-induced immune thrombotic thrombocytopenia (VITT).25,26

VITT is related to the anti-PF4 platelet-activating antibody, patients with VITT occur thrombocytopenia and thrombosis without heparin exposure.27-28 Studies have shown that VITT anti-PF4 antibodies had a stronger binding reaction than HIT antibodies to the PF4 and PF4/heparin complexes, which collect the PF4 tetramers to cluster and form immune complexes, thereby causing the FcγRIIA dependent platelet activation. Adverse reactions after adenoviral-vectored vaccination include microvascular damage, micro-bleeding and thrombosis, which are the result of released platelet activation and PF4-directed autoimmunity of VITT antibody.29,30

HIT and VITT mechanism shows in Figure 1.

### Table 1. Types of COVID-19 Vaccine.

| Name            | Company                    | Types                      | Efficacy (%) | Storage condition (°C) | Capacity (billion) |
|-----------------|----------------------------|----------------------------|--------------|------------------------|-------------------|
| BNT162b2        | Prizer(US)&BioNTech(GER)   | mRNA                      | 95.00        | −70                    | 1.07              |
| mRNA-1273       | Moderna(US)                | mRNA                      | 94.50        | −20                    | 0.5-1             |
| CoronaVac       | Sinovac Biotech(CHN)       | Inactivated viruses        | 91.25        | 2-8                    | 0.206             |
| BBIBP-CorV      | Beijing Institute of Biological Products(CHN) | adenovirus vector        | 86.00        | 2-8                    | 1.12              |
| Sputnik V       | Gamaleya(Russia)           | adenovirus vector          | 92.00        | 2-8                    | 1.2               |
| AZD1222         | Asrazeneca(UK)&Oxford      | adenovirus vector (ChAdOx1) | 70.40        | 2-8                    | 2.1               |
| NVX-CoV2373     | Novavax(US)                | mRNA                      | 89.30        | 2-8                    | 2                 |
| Ad26.COV2.s     | Johnson & Johnson(US)      | adenovirus vector(Ad26.COV2.s) | 66.90        | 2-8                    | 1                 |
| ConvideciaTM    | CanSino Bio(CHN)           | adenovirus vector(Ad5-nCoV) | 65.28        | 2-8                    | 0.1-0.2           |

*The data and contents listed in the table refer to references.*

2Clinical and Applied Thrombosis/Hemostasis
Adenovirus Vectors are Associated with Platelets

According to the proposed model, any adenovirus-vectored-DNA vaccine could drive autoimmune VITT in susceptible individuals. Electrochemical DNA–PF4 interactions and PF4–heparin interactions, but at different locations, represent the common denominator in HIT and VITT related autoimmune-mediated thrombosis.

It has confirmed that some adenoviruses can use coxsackie and adenovirus receptor (CAR) to bind to platelets. The replication-deficient recombinant chimpanzee ChAdOx1 vector, which is the main component of the Asrazeneca AZD1222 vaccine, uses CAR. However, Johnson & Johnson’s Ad26.COV2.S vaccine does not use CAR as the primary entry receptor. If thrombocytopenia and thrombosis occur after Johnson & Johnson’s vaccination, or have target PF4–heparin antibody response, considered that related to the adenovirus vector.

How to Prevent and Treat Thrombocytopenia and Thrombosis Caused by Adenovirus-Vector COVID-19 Vaccine?

Although researchers have not yet been able to confirm what component of the COVID-19 vaccine, caused this rare thrombocytopenia and thrombosis symptom, the following suggestions still have some reference value:

- If the patient has venous or arterial thrombosis in unusual parts (brain, abdomen) within 5 to 20 days after COVID-19 vaccine, consider the development of HIT or VITT and take appropriate measures.

Figure 1. HIT and VITT mechanism schematic. Abbreviations: HIT, heparin-induced thrombocytopenia; VITT, vaccine-induced immune thrombotic thrombocytopenia.
vaccination, or accompanied thrombocytopenia, it indicates vaccination adverse reactions.

For patients who have not been exposed to heparin recently but have thrombosis or thrombocytopenia, the PF4–heparin antibody can be detected. This is indicative for the determination of thrombocytopenia or anti-pf4 antibody-related thrombosis after COVID-19 vaccination.

Given that VITT has the same laboratory findings and clinical manifestations as HIT, the use of unfraction heparin (UFH) or LMWH and, or platelet transfusion therapy may lead to disease progression. In contrast, non-heparin anticoagulants and intravenous immunoglobulin (IVIG) therapy are often associated with rehabilitation.

**Conclusion**

Overall, adverse events associated with adenovirus-vectored COVID-19 vaccination was less than 1 in 1 million. The European Medicines Agency has determined that AstraZeneca’s COVID-19 vaccine is effective and recommended, thrombosis should list as an “extremely rare” side effect. The agency also stated that there is a “possible link” between AstraZeneca’s vaccine and thrombosis, but the existing data are not yet sufficient to confirm specific risk factors. The overall benefits of this vaccine outweigh the disadvantages.

According to current research results, we have known that the adenovirus-vector vaccine activates platelets and produce PF4 antibodies, but only a subset of sensitized patients progress to life-threatening complications of thrombocytopenia and thrombosis, the reasons and mechanisms need to be further explored.

**Compliance with ethics guidelines**

This article does not contain any studies with human or animal subjects performed.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship and/or publication of this article.

**ORCID iD**

Haimei MA https://orcid.org/0000-0002-2715-7732

**References**

1. Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. Epub 2020 Dec 10. PMID: 33301246; PMCID: PMC7745181. doi:10.1056/NEJMoa2034577

2. Baden LR, El Sahly HM, Essink B, et al. COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. Epub 2020 Dec 30. PMID: 3337869; PMCID: PMC7787219. doi:10.1056/NEJMoa2035389

3. Turkey declared Sinovac’s new coronavirus vaccine effective, http://www.saglik.gov.tr/, 2020 Dec 25.

4. Doroftei B, Ciобica A, Ilie OD, Maftie R, Ilea C. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics (Basel). 2021;11(4):579. PMID: 33804914; PMCID: PMC8063839. doi:10.3390/diagnostics11040579

5. Bucci E, Andreew K, Bjorkman A, et al. Safety and efficacy of the Russian COVID-19 vaccine: more information needed. Lancet. 2020;396(10256):e53. Epub 2020 Sep 21. PMID: 32971041; PMCID: PMC7503114. doi:10.1016/S0140-6736(20)31960-7

6. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72-74. Epub 2020 Dec 8. PMID: 33306990; PMCID: PMC7832220. doi:10.1016/S0140-6736(20)32623-4

7. https://ir.novavax.com/news-releases/news-release-details/novavax-x-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3

8. Shinde V, Bhikha S, Hoosain Z, et al. 2019nCoV-501 Study Group. Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. N Engl J Med. 2021;384:2187-2201. doi:10.1056/NEJMoa2103055

9. Sadoff J, Gray G, Vandebosch A, et al. ENSEMBLE Study Group. Safety and efficacy of NVX-CoV2373 covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1899-1909. Epub ahead of print. PMID: 33951374; PMCID: PMC8091623. doi:10.1056/NEJMoa2101544. Epub ahead of print. PMID: 33882225.

10. Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5 vectored COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano. 2020;14(10):12522-12537. Epub 2020 Oct 9. PMID: 33034449; PMCID: PMC7553041. doi:10.1021/acsnano.0c07197

11. Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 Vaccine frontrunners and their nanotechnology design. ACS Nano. 2020;14(10):12522-12537. Epub 2020 Oct 9. PMID: 33034449; PMCID: PMC7553041. doi:10.1021/acsnano.0c07197

12. Oliver SE, Gargano JW, Marin M, et al. The advisory committee on immunization practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1922-1924. PMID: 33332292; PMCID: PMC7745957. doi:10.15585/mmwr.mm6950e2

13. Smadja DM, Yue Q-Y, Choceron R, et al. Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase. Eur Respir J. 2021; in press. doi:10.1183/13993003.00956-2021.

14. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots

15. Schultz NH, Sorvoll HI, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384:2124–2130. doi:10.1056/NEJMoa2104882. Epub ahead of print. PMID: 33835768.
16. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrlie PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *N Engl J Med*. 2021;NEJMoa2104840. doi:10.1056/NEJMoa2104840. Epub ahead of print. PMID: 33835769; PMCID: PMC8095372.

17. Philippe A, Chocron R, Gendron N, et al. Circulating Von Willebrand factor and high molecular weight platelet multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. *Angiogenesis*. 2021;24(3):505–517.

18. Jevnikar M, Sanchez O, Chocron R, et al. Prevalence of pulmonary embolism in patients with COVID 19 at the time of hospital admission. *Eur Respir J*. 2021;58(1):2100116.

19. Huertas A, Montani D, Savale L, et al. Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? *Eur Respir J*. 2020;56(1):2001634. doi:10.1183/13993003.01634-2020.

20. Chocron R, Galand V, Cellier J, et al. Anticoagulation prior to hospitalization is a potential protective factor for COVID-19: insight from a French multicenter cohort study. *J Am Heart Assoc*. 2021;e018288.

21. Haimei MA. Pathogenesis and treatment strategies of COVID-19-related hypercoagulant and thrombotic complications. *Clin Appl Thromb Hemost*. 2020;26:1076029620944497. PMID: 32722927; PMCID: PMC7391437. doi:10.1177/1076029620944497.

22. Arepally GM. Heparin-induced thrombocytopenia. *Blood*. 2017;129(21):2864-2872. Epub 2017 Apr 17. PMID: 28416511; PMCID: PMC5445568. doi:10.1182/blood-2016-11-709873.

23. Oldenburg J, Klamroth R, Langer F, et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. *Hamostaseologie*. 2021;41(3):184–189. doi:10.1055/a-1469-7481. Epub ahead of print. Erratum in: Hamostaseologie. 2021 May 12: PMID: 33822348.

24. Wines BD, Tan CW, Duncan E, et al. Dimeric FcR ectodomains detect pathogenic anti-platelet factor 4-heparin antibodies in heparin-induced thrombocytopenia. *J Thromb Haemost*. 2018;16(12):2520-2525. Epub 2018 Nov 20. PMID: 30269432; PMCID: PMC6635755. doi:10.1111/jth.14306.

25. Aleem A, Nadeem AJ. Coronavirus (COVID-19) vaccine-induced immune thrombocytopenic purpura. *J Virol*. 2021;95(20):e01828. doi:10.1128/JVI.00928-12. PMID: 34051613; PMCID: PMC3457266. doi:10.1128/JVI.00928-12.

26. Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombocytopenia. *N Engl J Med*. 2021;384(23):2254-2256. Epub 2021 Apr 16. Erratum in: N Engl J Med. 2021 Jun 10;384(23):e92. PMID: 33861524; PMCID: PMC8063912. doi:10.1056/NEJMoa2106315.

27. Huynh A, Kelton JG, Arnold DM, Daka M, Nazy I. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopenia. *Nature*. 2021;596:565–569. doi:10.1038/s41586-021-03744-4. Epub ahead of print. PMID: 34233346.

28. McGonagle D, De Marco G, Bridgewood C. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection. *J Autoimmun*. 2021;121:102662. Epub 2021 May 19. PMID: 34051613; PMCID: PMC8133385. doi:10.1016/j.jaut.2021.102662.

29. Makris M, Pavord S, Lester W, Scully M, Hunt B. Vaccine-induced immune thrombocytopenia and thrombosis (VITT). *Res Pract Thromb Haemost*. 2021;5:e12529. doi:10.1002/rth.2.12529.

30. Franchini M, Liiumbruno GM, Pezzo M. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): diagnostic and therapeutic recommendations for a new syndrome. *Eur J Haematol*. 2021;100(1):1-8. doi:10.1111/ejh.13665.

31. Rzynski P, Perek B, Flišiar K. Thrombotic thrombocytopenia after COVID-19 vaccination: in search of the underlying mechanism. *Vaccines (Basel)*. 2021;9(6):559. PMID: 34071883; doi:10.3390/vaccines9060559.

32. Gupalo E, Buriachovskaia L, Othman M. Human platelets express CAR with localization at the sites of intercellular interaction. *Virol J*. 2011;8:456. PMID: 21962080; PMCID: PMC3192782. doi:10.1186/1743-422X-8-456.

33. Dicks MD, Spencer AJ, Coughlan L, et al. Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. *Sci Rep*. 2015;5:16756. PMID: 26576856; PMCID: PMC4649739. doi:10.1038/srep16756.

34. Li H, Rhee EG, Masek-Hammerman K, Teigler JE, Abbink P, Barouch DH. Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. *J Virol*. 2012;86(19):10862-5. Epub 2012 Jul 18. PMID: 22811531; PMCID: PMC3457266. doi:10.1128/JVI.00928-12.

35. Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after COVID-19 vaccination. *Autoimmun Rev*. 2021;20(9):102662. Epub 2021 May 19. PMID: 33852795; PMCID: PMC8063883. doi:10.1016/j.autrev.2021.102662.

36. Arepally GM, Ortel TL. Vaccine-induced immune thrombocytopenia: what we know and don’t know. *Blood*. 2021;blood.2021012152. doi:10.1182/blood.2021012152. Epub ahead of print. PMID: 34061166; PMCID: PMC8172307.